Streetbeat News

Products Services

A

ABT

BDX

The Biden administration has announced that it will restart the distribution of free at-home COVID-19 tests to American households. The U.S. Department of Health and Human Services (HHS) plans to distribute these tests, which can identify current COVID variants, starting next Monday. HHS has also invested $600 million in 12 domestic COVID-19 test manufacturers, expecting to secure approximately 200 million tests from these companies.

Portfolio Pulse from Vandana Singh

September 21, 2023 | 11:16 am

OPRA

Opera GX, the gaming browser developed by Opera Limited (NASDAQ: OPRA), has surpassed 25 million monthly active users.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:08 am

HSDT

Helius Medical Technologies, Inc. plans to showcase its Portable Neuromodulation Stimulator (PoNS) therapy at the 2023 Academy of Neurologic Physical Therapy Conference. The therapy is designed to improve gait in people with Multiple Sclerosis (MS). This will be the company's first-ever ANPT booth sponsorship.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:07 am

VEEV

Palleos Healthcare has chosen Veeva Systems' Vault Clinical Data Management Suite (CDMS) to unify all clinical study data on one platform. The suite includes Veeva Vault EDC and Veeva CDB, which will allow Palleos to manage high volumes of data from multiple sources, including wearables that monitor patient health status. This will provide real-time insight into how a study is progressing, enabling better assessment and management of outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:05 am

MDT

Medtronic Diabetes has received CE Mark for its new Simplera CGM, which is 50% smaller than its previous generation and offers a simple insertion and improved user experience.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:04 am

NAMS

NewAmsterdam Pharma has announced initial data from its Phase 2A trial of Obicetrapib in early Alzheimer's disease patients carrying at least one copy of the Apolipoprotein E4 mutation. The data showed potential improvement of cholesterol metabolism in the brain.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:03 am

TNXP

Tonix Pharmaceuticals presented new preclinical data at the Seventh International Cancer Immunotherapy Conference 2023. The data shows that mTNX-1700 suppresses tumor growth and increases survival rates in preclinical colorectal cancer models. It also shows single agent activity and additive effects in combination with anti-PD-1. mTNX-1700 targets myeloid-derived suppressor cells (MDSCs) in a novel mechanism to treat cancer.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:02 am

TRDA

Entrada Therapeutics has announced the dosing of its first participant in a Phase 1 clinical trial for ENTR-601-44, a potential treatment for Duchenne Muscular Dystrophy. The company expects to have data from the trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:01 am

INFY

Nigeria's Guaranty Trust Bank has chosen Infosys Finacle for its digital banking transformation across multiple countries. This could potentially increase Infosys' revenues and strengthen its position in the digital banking sector.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 10:56 am

AMZN

VIAV

Viavi Solutions Inc. (NASDAQ:VIAV) has unveiled Observer Sentry, a Software-as-a-Service-based Threat Exposure Management tool for AWS environments. The product will be showcased at InfoSec World from September 25-27, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 10:32 am